Soliris (eculizumab) for aHUS has been granted a positive recommendation to be placed on the National Health Service (NHS) in
On January 28, 2015, exactly two years and nine days after aHUS UK were informed Soliris would be referred for evaluation to the National Institute for Health Care and Excellence (NICE) sub-committee, the Highly Specialised Therapies Evaluation Committee, the evaluation process has concluded with Soliris being given the green light.
Soliris will be the most expensive treatment to be funded by the NHS to date.
An estimated 200 people are living with atypical Haemolytic Uraemic Syndrome (aHUS) in the UK.
According the Daily Mail, following the NICE recommendation, NHS officials agreed that at a cost of £340,000 (AUD $652,477) per patient each year, Soliris is value for money.
Explaining their recommendation to fund Soliris, NICE said, “[Soliris] was a ‘significant innovation’ and ‘offered gains of a magnitude rarely seen in any new drug treatment’.”
During its research and evaluation of Soliris, NICE identified that, on average, Soliris offers patients living with the ultra-rare, life-threatening disease “an extra 25 years of good-quality life.”
The Daily Mail reported Kidney Research UK was “thrilled with NICE’s decision”, citing “[Soliris] has been proven to prevent kidney failure in patients with newly diagnosed aHUS.
“Without it [Soliris], their kidneys would fail, and as there are no other effective treatments available, patients would have no choice but to start a gruelling dialysis routine to stay alive,” a Kidney Research UK spokesman said.
The NHS is currently in discussions with Soliris manufacturer, Alexion to reduce the cost of Soliris.
Read a full copy of the NICE guidance for Soliris for aHUS here.